NASDAQ:PRDS Pardes Biosciences (PRDS) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.16▼$2.1650-Day Range$2.13▼$2.1652-Week Range$0.75▼$3.93Volume400 shsAverage Volume359,530 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pardes Biosciences alerts: Email Address Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About Pardes Biosciences Stock (NASDAQ:PRDS)Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.Read More Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. PRDS Stock News HeadlinesOctober 31, 2023 | yahoo.comPardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo WeatherAugust 31, 2023 | finance.yahoo.comPardes Biosciences Announces Closing of Tender OfferSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 28, 2023 | finance.yahoo.comMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesAugust 17, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 3, 2023 | msn.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28July 19, 2023 | marketwatch.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…July 18, 2023 | msn.comJMP Securities Downgrades Pardes Biosciences (PRDS)July 17, 2023 | benzinga.comPRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to ShareholdersJuly 17, 2023 | msn.comPardes Biosciences stock rallies on buyout offer from MediPacificJuly 17, 2023 | benzinga.comWhy Pardes Biosciences Shares Are Rising MondayJuly 17, 2023 | markets.businessinsider.comPardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-marketJuly 17, 2023 | finance.yahoo.comPardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsJune 5, 2023 | finance.yahoo.comAll You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to BuyMay 17, 2023 | seekingalpha.comPardes Biosciences Seeking Strategic AlternativesMay 9, 2023 | markets.businessinsider.comPardes Biosciences (PRDS) Receives a Hold from SVB SecuritiesSee More Headlines Receive PRDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PRDS CUSIPN/A CIK1822711 Webwww.pardesbio.com Phone415-649-8758FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.36% Return on Assets-40.71% Debt Debt-to-Equity RatioN/A Current Ratio81.72 Quick Ratio81.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.86Miscellaneous Outstanding Shares62,012,000Free Float36,711,000Market Cap$133.95 million OptionableNot Optionable Beta0.42 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas G. Wiggans (Age 71)CEO & Chairman Comp: $859.4kDr. Uri A. Lopatin M.D. (Age 51)Founder & Director Comp: $786.96kMs. Heidi Henson CPA (Age 57)Chief Financial Officer Comp: $564.6kMs. Elizabeth Haber Lacy J.D. (Age 56)Gen. Counsel & Corp. Sec. Key CompetitorsActuate TherapeuticsNASDAQ:ACTUAccretion AcquisitionNASDAQ:ENERHome Plate AcquisitionNASDAQ:HPLTEndurance AcquisitionNASDAQ:EDNCLianBioNASDAQ:LIANView All Competitors This page (NASDAQ:PRDS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pardes Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.